These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22590588)

  • 1. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
    Delaugerre C; Gallien S; Flandre P; Mathez D; Amarsy R; Ferret S; Timsit J; Molina JM; de Truchis P
    PLoS One; 2012; 7(5):e36673. PubMed ID: 22590588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China.
    Liu P; You Y; Liao L; Feng Y; Shao Y; Xing H; Lan G; Li J; Ruan Y; Li D
    BMC Infect Dis; 2022 May; 22(1):426. PubMed ID: 35509014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.
    Gonzalez-Serna A; Min JE; Woods C; Chan D; Lima VD; Montaner JS; Harrigan PR; Swenson LC
    Clin Infect Dis; 2014 Apr; 58(8):1165-73. PubMed ID: 24429436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.
    Palich R; Wirden M; Peytavin G; Lê MP; Seang S; Abdi B; Schneider L; Tubiana R; Valantin MA; Paccoud O; Soulié C; Calvez V; Katlama C; Marcelin AG
    J Antimicrob Chemother; 2020 Oct; 75(10):2981-2985. PubMed ID: 32642769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
    Vardhanabhuti S; Taiwo B; Kuritzkes DR; Eron JJ; Bosch RJ
    Antivir Ther; 2015; 20(1):73-6. PubMed ID: 24699164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
    Bai R; Lv S; Hua W; Su B; Wang S; Shao Y; Li Z; Liu A; Sun L; Dai L
    HIV Med; 2022 Mar; 23 Suppl 1():72-83. PubMed ID: 35293102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
    Kantor R; DeLong A; Schreier L; Reitsma M; Kemboi E; Orido M; Obonge S; Boinett R; Rono M; Emonyi W; Brooks K; Coetzer M; Buziba N; Hogan J; Diero L
    AIDS; 2018 Nov; 32(17):2485-2496. PubMed ID: 30134290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
    Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
    AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana.
    Bareng OT; Moyo S; Zahralban-Steele M; Maruapula D; Ditlhako T; Mokaleng B; Mokgethi P; Choga WT; Moraka NO; Pretorius-Holme M; Mine MO; Raizes E; Molebatsi K; Motswaledi MS; Gobe I; Mohammed T; Gaolathe T; Shapiro R; Mmalane M; Makhema JM; Lockman S; Essex M; Novitsky V; Gaseitsiwe S
    J Antimicrob Chemother; 2022 Apr; 77(5):1385-1395. PubMed ID: 35229102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis.
    Taramasso L; Magnasco L; Bruzzone B; Caligiuri P; Bozzi G; Mora S; Balletto E; Tatarelli P; Giacomini M; Di Biagio A
    J Clin Virol; 2020 Feb; 123():104255. PubMed ID: 31927152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study.
    Sudjaritruk T; Teeraananchai S; Kariminia A; Lapphra K; Kumarasamy N; Fong MS; Hansudewechakul R; Bunupuradah T; Ly PS; Nallusamy RA; Sohn AH; Sirisanthana V;
    J Int AIDS Soc; 2020 Jul; 23(7):e25550. PubMed ID: 32628816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
    Li JZ; Gallien S; Do TD; Martin JN; Deeks S; Kuritzkes DR; Hatano H
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5998-6000. PubMed ID: 22890763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
    Gallien S; Delaugerre C; Charreau I; Braun J; Boulet T; Barrail-Tran A; de Castro N; Molina JM; Kuritzkes DR
    AIDS; 2011 Mar; 25(5):665-9. PubMed ID: 21326075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy.
    Gaifer Z; Boulassel MR
    J Int Assoc Provid AIDS Care; 2020; 19():2325958220979817. PubMed ID: 33372823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.
    Swenson LC; Min JE; Woods CK; Cai E; Li JZ; Montaner JS; Harrigan PR; Gonzalez-Serna A
    AIDS; 2014 May; 28(8):1125-34. PubMed ID: 24451160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.
    Hsu JY; Sun HY; Hsieh TW; Chang SY; Chuang YC; Huang YS; Hsiao CY; Su YC; Liu WC; Chang SF; Hung CC
    J Glob Antimicrob Resist; 2022 Jun; 29():7-16. PubMed ID: 35172201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
    Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.
    Zhang T; Ding H; An M; Wang X; Tian W; Zhao B; Han X
    BMC Infect Dis; 2020 Feb; 20(1):147. PubMed ID: 32066392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 low-level viremia affects T cell activation rather than T cell development in school-age children, adolescents, and young adults during antiretroviral therapy.
    Han J; Mu W; Zhao H; Hao Y; Song C; Zhou H; Sun X; Li G; Dai G; Zhang Y; Zhang F; Zeng H
    Int J Infect Dis; 2020 Feb; 91():210-217. PubMed ID: 31821891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.